## üìã Pharmacovigilance Assessment

### ‚ö†Ô∏è CRITICAL SAFETY FLAGS IDENTIFIED

#### 1. **INCOMPLETE MEDICATION ORDER ‚Äî ACTION REQUIRED**
The handoff notes "administer PRN opioid if pain >6/10," but **no specific opioid agent, dose, or route is prescribed**. This is an incomplete order that requires clarification before administration.

**Concerns:**
- **Respiratory depression risk:** SpO2 93% on RA + RR 22/min suggests early respiratory compromise; opioids could precipitate decompensation
- **Bleeding risk with enoxaparin:** Most opioids are acceptable, but concurrent anticoagulation requires monitoring
- **Standard of care:** PRN orders must be specific

**‚Üí RECOMMENDATION:** Verify specific opioid order (e.g., morphine, oxycodone, hydromorphone) with prescriber before administration.

---

#### 2. **ELEVATED TROPONIN + ANTICOAGULATION MONITORING**
- **Troponin:** 0.11 ng/mL (Elevated) ‚Äî possible cardiac injury, NSTEMI, or demand ischemia
- **Enoxaparin:** 40mg SC daily active

**Concerns:**
- Elevated troponin in cancer patients may indicate true ACS, demand ischemia, or pulmonary embolism (higher risk in lung cancer)
- Anticoagulation requires close monitoring for bleeding signs, especially if intervention needed

**‚Üí RECOMMENDATION:** Hold enoxaparin pending cardiology review if ACS suspected; monitor for bleeding.

---

#### 3. **ENOXAPARIN DUPLICATION CONFIRMED**
As noted by Refiner: Two entries for Enoxaparin 40mg daily in source documentation.

**‚Üí RECOMMENDATION:** Verify against MAR. If order is truly duplicated, discontinue duplicate entry to avoid accidental extra dosing.

---

#### 4. **CHEMORADIATION + ANTICOAGULATION = ELEVATED BLEED RISK**
- Myelosuppression from chemoradiation increases bleeding susceptibility
- Daily enoxaparin compounding risk

**‚Üí RECOMMENDATION:** Monitor CBC trends (hemoglobin currently stable at 9.7 g/dL); assess for signs of bleeding with each shift.

---

### ‚úÖ NO DRUG-DRUG INTERACTIONS FLAGGED
- NKDA documented
- No identified direct contraindications with current active meds

---

### üìù SUMMARY ACTION ITEMS
| Priority | Action |
|----------|--------|
| üî¥ HIGH | Verify specific PRN opioid order (agent, dose, route) before administration |
| üî¥ HIGH | Assess enoxaparin necessity vs. bleeding risk given elevated troponin |
| üü° MED | Resolve enoxaparin duplication in MAR |
| üü° MED | Monitor CBC, bleeding signs q4‚Äì6h given anticoagulation + chemo |

---

*Assessment complete. Awaiting clarification on incomplete opioid order before full clearance.*